ReviewRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2019
Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens.
Review in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Protein-Protein Interactions Between Peptidoglycan, Lipopolysaccharide, and Phospholipid Biosynthesis Enzymes in Escherichia coli.Chembiochem : a European journal of chemical biology · 2026Article
- From Environmental Organism to Nosocomial Threat:Antibiotics (Basel, Switzerland) · 2026Review
- Antibiotic Mechanisms and Resistance: Molecular Insights and Therapeutic Strategies.Antibiotics (Basel, Switzerland) · 2026Review
- Fosfomycin Use in Treating Severe Difficult-to-Treat Gram-Negative Infections-A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2026Review
- Understanding the Burden and Management of Urinary Tract Infections in Women.Diseases (Basel, Switzerland) · 2025Review
- Effect of fosfomycin-induced hypernatremia on patients' hospital stay length and survival.Irish journal of medical science · 2024Article
- Unlocking the biosynthetic potential and taxonomy of the Antarctic microbiome along temporal and spatial gradients.Microbiology spectrum · 2024Article
- Antimicrobial Susceptibility Profiles ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Article
- In vitro synergy screens of FDA-approved drugs reveal novel zidovudine- and azithromycin-based combinations with last-line antibiotics against Klebsiella pneumoniae.Scientific reports · 2023Article
- Identification and analysis of small molecule inhibitors of FosB fromRSC medicinal chemistry · 2023Article
- Urinary Tract Infections: The Current Scenario and Future Prospects.Pathogens (Basel, Switzerland) · 2023Review
- Prescription Pattern of Intravenous Fosfomycin in a Provincial Hospital in Thailand.Infection & chemotherapy · 2022Article
- Assessment of the Susceptibility of Clinical Gram-Negative and Gram-Positive Bacterial Strains to Fosfomycin and Significance of This Antibiotic in Infection Treatment.Pathogens (Basel, Switzerland) · 2022Article
- Genomic analysis of Fosfomycin resistance in multi-drug resistant uropathogens and comparison ofIranian journal of microbiology · 2022Article
- Spread and Molecular Characteristics ofMicrobiology spectrum · 2022Article
- Synergistic activity and molecular modelling of fosfomycin combinations with some antibiotics against multidrug resistant Helicobacter pylori.World journal of microbiology & biotechnology · 2022Article
- Molecular Epidemiology of Fosfomycin ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Fosfomycin, Applying Known Methods and Remedies to A New Era.Diseases (Basel, Switzerland) · 2020Article
- The combined antimicrobial activity of citrus honey and fosfomycin on multidrug resistantAIMS microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The alarming increase in antibiotic resistance rates reported for various pathogens has resulted in the use of alternative treatment policies. Given the fairly limited availability of new antimicrobial drugs, the reassessment of older antibiotics is now an interesting option. Fosfomycin, a bactericidal analog of phosphoenolpyruvate that has been previously been employed as an oral treatment for uncomplicated urinary tract infection, has recently raised interest among physicians worldwide. In general, the advanced resistance described in Gram-negative bacteria suggests that fosfomycin can be an appropriate treatment option for patients with highly resistant microbial infections. This review, which refers to key available data, focuses on the possibility of extending the use of fosfomycin beyond urinary tract infections and against multidrug-resistant Gram-negative bacteria.
Indexed as
Identifiers
31131592PMC6555168W3010041137What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.